MA56049A - Formulations stabilisées contenant des anticorps anti-angptl3 - Google Patents
Formulations stabilisées contenant des anticorps anti-angptl3Info
- Publication number
- MA56049A MA56049A MA056049A MA56049A MA56049A MA 56049 A MA56049 A MA 56049A MA 056049 A MA056049 A MA 056049A MA 56049 A MA56049 A MA 56049A MA 56049 A MA56049 A MA 56049A
- Authority
- MA
- Morocco
- Prior art keywords
- formulations containing
- containing anti
- stabilized formulations
- angptl3 antibodies
- angptl3
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39591—Stabilisation, fragmentation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A61K9/0021—Intradermal administration, e.g. through microneedle arrays, needleless injectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Dermatology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Endocrinology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201962852643P | 2019-05-24 | 2019-05-24 |
Publications (1)
Publication Number | Publication Date |
---|---|
MA56049A true MA56049A (fr) | 2022-04-06 |
Family
ID=72179136
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MA056049A MA56049A (fr) | 2019-05-24 | 2020-05-24 | Formulations stabilisées contenant des anticorps anti-angptl3 |
Country Status (16)
Country | Link |
---|---|
US (1) | US20200369760A1 (fr) |
EP (1) | EP3976647A1 (fr) |
JP (1) | JP2022532927A (fr) |
KR (1) | KR20220011727A (fr) |
CN (1) | CN114007647A (fr) |
AU (1) | AU2020282956A1 (fr) |
BR (1) | BR112021023501A2 (fr) |
CA (1) | CA3139333A1 (fr) |
CL (1) | CL2021003026A1 (fr) |
CO (1) | CO2021016183A2 (fr) |
EA (1) | EA202193240A1 (fr) |
IL (1) | IL288153A (fr) |
MA (1) | MA56049A (fr) |
MX (1) | MX2021014332A (fr) |
SG (1) | SG11202112256SA (fr) |
WO (1) | WO2020243031A1 (fr) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20240035835A (ko) * | 2021-07-21 | 2024-03-18 | 지앙수 헨그루이 파마슈티컬스 컴퍼니 리미티드 | 항-angptl3 항체 또는 이의 항원 결합 단편의 약학적 조성물 및 이의 응용 |
WO2023122656A1 (fr) | 2021-12-22 | 2023-06-29 | Regeneron Pharmaceuticals, Inc. | Traitement de maladies rénales avec inhibiteurs de l'angiopoïétine de type 3 (angptl3) |
WO2023213779A1 (fr) | 2022-05-02 | 2023-11-09 | Novo Nordisk A/S | Nouveaux anticorps anti-angptl3 appropriés pour des compositions à concentration élevée et administration sous-cutanée |
WO2024102913A1 (fr) | 2022-11-10 | 2024-05-16 | Regeneron Pharmaceuticals, Inc. | Traitement de maladies rénales avec une combinaison d'inhibiteurs de type angiopoïétine 3 (angptl3) et d'inhibiteurs de membre 2 de la famille 5 des porteurs de solutés (slc5a2) |
Family Cites Families (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH0747045B2 (ja) | 1986-10-15 | 1995-05-24 | 株式会社大協精工 | 積層した注射器用滑栓 |
JP3100727B2 (ja) | 1992-01-23 | 2000-10-23 | 株式会社大協精工 | 変性ポリシロキサン組成物及び該組成物を被覆した衛生ゴム製品 |
JP3172057B2 (ja) | 1995-04-05 | 2001-06-04 | 株式会社大協精工 | ラミネートゴム栓 |
JP3512349B2 (ja) | 1999-01-29 | 2004-03-29 | 株式会社大協精工 | 柱状ゴム要素の成形型 |
US6629949B1 (en) | 2000-05-08 | 2003-10-07 | Sterling Medivations, Inc. | Micro infusion drug delivery device |
US6659982B2 (en) | 2000-05-08 | 2003-12-09 | Sterling Medivations, Inc. | Micro infusion drug delivery device |
JP2002209975A (ja) | 2001-01-19 | 2002-07-30 | Daikyo Seiko Ltd | 医薬バイアル用ラミネートゴム栓 |
MX2009006082A (es) | 2006-12-08 | 2009-08-18 | Lexicon Pharmaceuticals Inc | Anticuerpos monoclonales contra la proteina 3 similar a angiopoyetina (angptl3). |
AR070315A1 (es) * | 2008-02-07 | 2010-03-31 | Merck & Co Inc | Anticuerpos 1b20 antagonistas de pcsk9 |
AR087329A1 (es) * | 2011-06-17 | 2014-03-19 | Regeneron Pharma | Anticuerpos humanos contra proteina 3 de tipo angiopoietina humana |
EP2735315B1 (fr) * | 2011-07-19 | 2019-10-02 | Chugai Seiyaku Kabushiki Kaisha | Préparation à teneur en protéines stable renfermant de l'argininamide ou de la valinamide |
US11603407B2 (en) * | 2017-04-06 | 2023-03-14 | Regeneron Pharmaceuticals, Inc. | Stable antibody formulation |
-
2020
- 2020-05-22 US US16/882,280 patent/US20200369760A1/en active Pending
- 2020-05-24 CN CN202080046178.3A patent/CN114007647A/zh active Pending
- 2020-05-24 CA CA3139333A patent/CA3139333A1/fr active Pending
- 2020-05-24 EP EP20760579.1A patent/EP3976647A1/fr active Pending
- 2020-05-24 JP JP2021569354A patent/JP2022532927A/ja active Pending
- 2020-05-24 KR KR1020217042347A patent/KR20220011727A/ko unknown
- 2020-05-24 BR BR112021023501A patent/BR112021023501A2/pt unknown
- 2020-05-24 EA EA202193240A patent/EA202193240A1/ru unknown
- 2020-05-24 MX MX2021014332A patent/MX2021014332A/es unknown
- 2020-05-24 WO PCT/US2020/034438 patent/WO2020243031A1/fr active Application Filing
- 2020-05-24 MA MA056049A patent/MA56049A/fr unknown
- 2020-05-24 AU AU2020282956A patent/AU2020282956A1/en active Pending
- 2020-05-24 SG SG11202112256SA patent/SG11202112256SA/en unknown
-
2021
- 2021-11-16 IL IL288153A patent/IL288153A/en unknown
- 2021-11-16 CL CL2021003026A patent/CL2021003026A1/es unknown
- 2021-11-29 CO CONC2021/0016183A patent/CO2021016183A2/es unknown
Also Published As
Publication number | Publication date |
---|---|
WO2020243031A1 (fr) | 2020-12-03 |
EA202193240A1 (ru) | 2022-03-14 |
EP3976647A1 (fr) | 2022-04-06 |
KR20220011727A (ko) | 2022-01-28 |
MX2021014332A (es) | 2022-04-06 |
IL288153A (en) | 2022-01-01 |
AU2020282956A1 (en) | 2022-01-27 |
JP2022532927A (ja) | 2022-07-20 |
CO2021016183A2 (es) | 2021-12-10 |
SG11202112256SA (en) | 2021-12-30 |
CL2021003026A1 (es) | 2022-06-24 |
CA3139333A1 (fr) | 2020-12-03 |
CN114007647A (zh) | 2022-02-01 |
BR112021023501A2 (pt) | 2022-01-18 |
US20200369760A1 (en) | 2020-11-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MA49043A (fr) | Formulation stable d'anticorps | |
MA46820A (fr) | Composition pharmaceutique comprenant des constructions d'anticorps bi-spécifiques | |
MA44780A (fr) | Préparation contenant un anticorps | |
MA56049A (fr) | Formulations stabilisées contenant des anticorps anti-angptl3 | |
MA49726A (fr) | Formulation d'anticorps anti-cgrp | |
MA53434A (fr) | Anticorps anti-tigit | |
MA52884A (fr) | Anticorps anti-il-11 | |
MA50505A (fr) | Anticorps 2 + 1 bispécifiques (contorsbodies) | |
MA56006A (fr) | Formulations sous-cutanées d'anticorps her2 | |
MA44381A (fr) | Format d'anticorps hétérodimères multispécifiques | |
MA53356B1 (fr) | Formulations sous-cutanées d'anticorps anti-cd38 et leurs utilisations | |
MA43018B1 (fr) | Anticorps anti-pd1 et procédés d'utilisation | |
MA40576B1 (fr) | Anticorps et immunoconjugués anti-her2 | |
MA51903A (fr) | Formulations d'anticorps b7-h4 | |
MA55362A (fr) | Formulations stabilisées contenant des anticorps anti-il-33 | |
MA52366A (fr) | Anticorps anti-tl1a optimisés | |
MA53905A (fr) | Anticorps stabilisant trem2 | |
MA45450B1 (fr) | Formulations d'anticorps anti-cd19 | |
FR3022462B1 (fr) | Composition orale d'anticorps anti-tnfalpha | |
MA47494A (fr) | Nouvelles utilisations d'anticorps anti-sirpg | |
MA54052A (fr) | Formulation d'anticorps | |
MA52152A (fr) | Anticorps | |
MX2022001146A (es) | Formulaciones de anticuerpos anti-pvrig y sus usos. | |
MA54139A (fr) | Formulation d'anticorps | |
MA49116A (fr) | Compositions pharmaceutiques contenant de l'insuline |